Earnings call transcript: Sandoz Q3 2025 sees biosimilars boost growth
PositiveFinancial Markets

Sandoz's Q3 2025 earnings call revealed a significant boost in growth driven by their biosimilars portfolio. This is important as it highlights the increasing acceptance and demand for biosimilars in the market, which can lead to more affordable treatment options for patients. The company's performance reflects a positive trend in the pharmaceutical industry, showcasing innovation and the potential for expanded access to essential medications.
— Curated by the World Pulse Now AI Editorial System







